Company Will Unveil its Innovative Closed IV Catheter System to Address IV Therapy Challenges

Ann Arbor, MI -- (SBWIRE) -- 04/24/2012 -- Tangent Medical (http://www.tangentmedical.com), an innovator in IV therapy products, today announced its participation (Booth # 329) at the 2012 INS Annual Convention & Industrial Exhibition on April 30 - May 2, 2012 at the Rio Hotel in Las Vegas. The NovaCath™ Secure IV Catheter System, currently under 510(k) review with the FDA, will be unveiled to the public for the first time at this convention. NovaCath is a next-generation technology designed to address current IV therapy challenges including catheter stabilization, occupational exposure to blood, tubing management and patient comfort.

"Up to 50% of all short-peripheral IV catheters develop complications that negatively impact catheter dwell times, clinical outcomes, patient safety and patient satisfaction," said Curtis Bloch, Vice President of Sales and Marketing for Tangent Medical. "Most industry guidelines and standards recommend the use of catheter stabilization devices to preserve catheter site integrity and reduce complications. Our innovative, closed IV catheter design uniquely integrates advanced catheter stabilization technology, blood control and next generation tubing management on every short-peripheral IV start. The unveiling of NovaCath at INS will create a new paradigm in IV catheter design, functionality and performance."

When cleared by the FDA, NovaCath will be the first safety IV catheter offering advanced catheter stabilization technology designed to exceed the highest CDC, OSHA and INS standards for IV catheter stabilization. Its passive needle shielding technology and closed system is designed to minimize occupational exposure to blood. Several patent pending design features will uniquely position NovaCath to offer healthcare facilities uncompromising safety and satisfaction – both to the clinician and the patient.

The INS Annual Convention & Industrial Exhibition is the largest convention in the U.S. each year for the infusion specialty. This year between 1,300 and 1,500 infusion nurses from 30 countries will converge on Las Vegas for six days of education sessions, three days of exhibits with industry leaders, poster and abstract presentations showcasing the latest infusion research and plenty of networking opportunities.

About Tangent Medical
Tangent Medical is focused on the development and commercialization of IV therapy products. Founded in 2009 as a spin-out of the University of Michigan's Medical Innovation Center, the company's patent-pending NovaCath™ Secure IV Catheter System is the only safety IV catheter to cost-effectively integrate advanced catheter stabilization, passive needle encapsulation, tubing management and blood control. Based on extensive clinical research into the needs of both healthcare workers and patients, this next-generation system is designed to establish a new standard in catheter design, functionality and performance. For more information, visit http://www.tangentmedical.com.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Innovative Closed Catheter System To Offer Advanced Catheter Stabilization On Every Single Start

Ann Arbor, MI -- (SBWIRE) -- 04/16/2012 -- Tangent Medical (http://www.tangentmedical.com), an innovator in IV therapy products, today announced submission of a 510(k) for its NovaCath™ Secure IV Catheter System, developed from extensive clinical research of healthcare worker and patient needs. This new closed IV catheter system is a next-generation technology designed to address several complex IV therapy challenges including catheter stabilization, occupational exposure to blood, and patient discomfort. When cleared by the FDA, the NovaCath system will be the first safety IV catheter offering advanced catheter stabilization technology designed to exceed the highest CDC, OSHA, and INS standards for peripheral IV catheter stabilization.

"The NovaCath Secure IV System is a promising new IV catheter designed to advance the safety and welfare of both patients and healthcare workers," said Curtis Bloch, Vice President of Sales and Marketing. "It's designed to reduce overall IV complications including dislodgement, infiltration, phlebitis, and occlusion. Furthermore, its passive needle shielding technology and closed system is designed to minimize occupational exposure to blood. Several patent pending features will uniquely position the NovaCath System to offer healthcare facilities uncompromising safety – both to the clinician and the patient."

"The initial feedback on the NovaCath Secure IV Catheter System design has been extremely positive from both industry professionals and potential users," said Jeff Williams, CEO & Chairman, Tangent Medical. "We are excited to announce NovaCath's submission milestone and look forward to working with the FDA through the review process to gain 510(k) marketing clearance. The company has attracted an accomplished management team that is incredibly passionate about commercializing this innovative technology, which will be publicly unveiled for the first time in the coming weeks."

About Tangent Medical
Tangent Medical is focused on the development and commercialization of IV therapy products. Founded in 2009 as a spin-out of the University of Michigan's Medical Innovation Center, the company's patent-pending NovaCath™ Secure IV Catheter System is the only safety IV catheter to cost-effectively integrate advanced catheter stabilization, passive needle encapsulation and blood control. Based on extensive clinical research into the needs of both healthcare workers and patients, this next-generation system is designed to establish a new standard in catheter design, functionality and performance. For more information, visit http://www.tangentmedical.com.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm